Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
How would you approach SBRT in a pacemaker-dependent elderly patient with Stage I NSCLC whose SBRT plan Dmax exceeds the pacemaker tolerance?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
How do you treat Stage IIIC T4N3 NSCLC?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
